BACKGROUND AND OBJECTIVES: Extended-release naltrexone (XR-NTX) is FDA-approved to prevent relapse in patients with Opioid Use Disorder. However little is known about long-term use among community-based outpatients. METHODS: Retrospective chart review and long-term follow-up survey among individuals (N = 168) who entered an outpatient XR-NTX trial between 2011 and 2015, during which participants were offered three monthly injections of XR-NTX at no cost. The survey consisted of 35 questions covering a total of four domains: (1) substance use; (2) treatment continuation; (3) barriers; and (4) attitudes. RESULTS: Fifty-seven respondents were successfully surveyed, including 50% of those initially receiving all three XR-NTX injections ("study completers") in the parent study. Study completion was associated with superior outcomes and less likely relapse (defined as daily use), with a much greater time to relapse despite higher rates of concurrent non-opioid substance use. However the majority of participants discontinued treatment with XR-NTX at study completion, largely due to attitudes of "feeling cured" and "wanting to do it on my own" rather than external barriers such as cost or side effects. CONCLUSION: Patients who initiate treatment with XR-NTX might benefit from anticipatory guidance and motivational techniques to encourage long-term adherence as many will experience internal barriers to continuation. Our findings are reassuring that few patients experience side effects or adverse events complicating the effectiveness or safety of long-term use of XR-NTX. SCIENTIFIC SIGNIFICANCE: Among outpatients who successfully receive 3 monthly XR-NTX injections, many will prematurely discontinue treatment due to internal attitudes, such as "feeling cured." (Am J Addict 2017;26:319-325).
BACKGROUND AND OBJECTIVES: Extended-release naltrexone (XR-NTX) is FDA-approved to prevent relapse in patients with Opioid Use Disorder. However little is known about long-term use among community-based outpatients. METHODS: Retrospective chart review and long-term follow-up survey among individuals (N = 168) who entered an outpatientXR-NTX trial between 2011 and 2015, during which participants were offered three monthly injections of XR-NTX at no cost. The survey consisted of 35 questions covering a total of four domains: (1) substance use; (2) treatment continuation; (3) barriers; and (4) attitudes. RESULTS: Fifty-seven respondents were successfully surveyed, including 50% of those initially receiving all three XR-NTX injections ("study completers") in the parent study. Study completion was associated with superior outcomes and less likely relapse (defined as daily use), with a much greater time to relapse despite higher rates of concurrent non-opioid substance use. However the majority of participants discontinued treatment with XR-NTX at study completion, largely due to attitudes of "feeling cured" and "wanting to do it on my own" rather than external barriers such as cost or side effects. CONCLUSION:Patients who initiate treatment with XR-NTX might benefit from anticipatory guidance and motivational techniques to encourage long-term adherence as many will experience internal barriers to continuation. Our findings are reassuring that few patients experience side effects or adverse events complicating the effectiveness or safety of long-term use of XR-NTX. SCIENTIFIC SIGNIFICANCE: Among outpatients who successfully receive 3 monthly XR-NTX injections, many will prematurely discontinue treatment due to internal attitudes, such as "feeling cured." (Am J Addict 2017;26:319-325).
Authors: Shanthi Mogali; Nabil A Khan; Esther S Drill; Martina Pavlicova; Maria A Sullivan; Edward Nunes; Adam Bisaga Journal: Am J Addict Date: 2015-04
Authors: Donna M Coviello; James W Cornish; Kevin G Lynch; Tamara Y Boney; Cynthia A Clark; Joshua D Lee; Peter D Friedmann; Edward V Nunes; Timothy W Kinlock; Michael S Gordon; Robert P Schwartz; Elie S Nuwayser; Charles P O'Brien Journal: Subst Abus Date: 2012 Impact factor: 3.716
Authors: Jennifer Sharpe Potter; Jessica A Dreifuss; Elise N Marino; Scott E Provost; Dorian R Dodd; Lindsay S Rice; Garrett M Fitzmaurice; Margaret L Griffin; Roger D Weiss Journal: J Subst Abuse Treat Date: 2014-08-02
Authors: Evgeny Krupitsky; Edward V Nunes; Walter Ling; Ari Illeperuma; David R Gastfriend; Bernard L Silverman Journal: Lancet Date: 2011-04-30 Impact factor: 79.321
Authors: Kenneth M Carpenter; Huiping Jiang; Maria A Sullivan; Adam Bisaga; Sandra D Comer; Wilfrid Noel Raby; Adam C Brooks; Edward V Nunes Journal: Psychol Addict Behav Date: 2009-03
Authors: Evgeny Krupitsky; Edward V Nunes; Walter Ling; David R Gastfriend; Asli Memisoglu; Bernard L Silverman Journal: Addiction Date: 2013-05-24 Impact factor: 6.526
Authors: Kenneth Blum; Edward J Modestino; Rajendra D Badgaiyan; David Baron; Panayotis K Thanos; Igor Elman; David Siwicki; Marcelo Febo; Mark S Gold Journal: EC Psychol Psychiatr Date: 2018-07-30
Authors: Eric R Braverman; Catherine A Dennen; Mark S Gold; Abdalla Bowirrat; Ashim Gupta; David Baron; A Kenison Roy; David E Smith; Jean Lud Cadet; Kenneth Blum Journal: Int J Environ Res Public Health Date: 2022-04-30 Impact factor: 4.614
Authors: Brantley P Jarvis; August F Holtyn; Shrinidhi Subramaniam; D Andrew Tompkins; Emmanuel A Oga; George E Bigelow; Kenneth Silverman Journal: Addiction Date: 2018-03-24 Impact factor: 6.526
Authors: Kathleen M Carroll; Charla Nich; Tami L Frankforter; Sarah W Yip; Brian D Kiluk; Elise E DeVito; Mehmet Sofuoglu Journal: Drug Alcohol Depend Date: 2018-10-04 Impact factor: 4.492
Authors: Claudia R Amura; Tanya R Sorrell; Mary Weber; Andrea Alvarez; Nancy Beste; Ursula Hollins; Paul F Cook Journal: Subst Abuse Treat Prev Policy Date: 2022-01-03
Authors: Miranda G Greiner; Matisyahu Shulman; Tse-Hwei Choo; Jennifer Scodes; Martina Pavlicova; Aimee N C Campbell; Patricia Novo; Marc Fishman; Joshua D Lee; John Rotrosen; Edward V Nunes Journal: J Subst Abuse Treat Date: 2021-04-30